Name | Rp-8-CPT-cAMPS sodium |
---|
Description | Rp-8-CPT-cAMPS sodium, a cAMP analog, is a potent and competitive antagonist of cAMP-induced activation of cAMP-dependent PKA I and II. Rp-8-CPT-cAMPS sodium preferentially selects site A of RI compares to site A of RII and site B of RII compares to site B of RI[1][2]. |
---|---|
Related Catalog | |
Target |
PKA[1] |
In Vitro | Rp-8-CPT-cAMPS (100 μM; 15 min) blocks phosphorylation of VASP by 6-Bnz-cAMP and largely reduces VASP phosphorylation by forskolin and fenoterol[2]. Rp-8-CPT-cAMPS (100 μM; 30 min) reduces GTP-loading of Rap1 by both 8-pCPT-2'-O-Me-cAMP and 6-Bnz-cAMP[2]. Rp-8-CPT-cAMPS (100 μM; 30 min) largely diminishes the augmentation of bradykinin-induced IL-8 release by the PKA activator 6-Bnz-cAMP and the Epac activator 8-pCPT-2'-O-Me-cAMP[2]. Rp-8-CPT-cAMPS (10 μM) inhibits the endothelium-dependent and -independent relaxation which induced by Venom in pre-contracted rat mesenteric artery rings[3]. |
References |
Molecular Formula | C16H14ClN5NaO5PS2 |
---|---|
Molecular Weight | 509.86 |